Search
SSR-126517E
go.drugbank.com/drugs/DB05362ExperimentalSSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
AC-100
go.drugbank.com/drugs/DB05671InvestigationalAC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells (a fragment from matrix extracellular phosphoglycoprotein).
YSIL6
go.drugbank.com/drugs/DB05017ExperimentalYSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. … The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.
Afelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
TC-5231
go.drugbank.com/drugs/DB05333ExperimentalTC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine. … TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder).
Thiethylperazine
go.drugbank.com/drugs/DB00372ApprovedInvestigationalWithdrawnA dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.
NV-18
go.drugbank.com/drugs/DB05886ExperimentalLike phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer
PSN357
go.drugbank.com/drugs/DB05044ExperimentalPSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.
Nirogacestat
go.drugbank.com/drugs/DB12005ApprovedInvestigationalDesmoid tumors are typically characterized by aberrant activation in Notch signaling. … It was previously granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase
Imazaquin
go.drugbank.com/drugs/DB04582ExperimentalCategories: Compounds used in a research, industrial, or household setting